Research programme: LUNAR FLU - Arcturus Therapeutics
Alternative Names: LUNAR-FLU - Arcturus TherapeuticsLatest Information Update: 28 Aug 2024
At a glance
- Originator Arcturus Therapeutics
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Dendritic cell modulators; Protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (IM)
- 21 Dec 2022 Arcturus enters into a collaboration with Seqirus to develop and commercialise self-amplifying mRNA vaccines (Arcturus Therapeutics pipeline, December 2022)
- 21 Dec 2022 Arcturus Therapeutics and BARDA collaborates for LUNAR FLU for Influenza (Arcturus Therapeutics pipeline, December 2022)